Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Andropause
QuatRx Pharmaceuticals Company initiates phase II trial of fispemifene for andropause
March 24th, 2006
QuatRx Pharmaceuticals Company announced the initiation of a phase II clinical trial for fispemifene, the company's product candidate for the treatment of the symptoms of andropause. Fispemifene is the company's product candidate for the treatment of the symptoms of andropause. This first randomized, double-blind, placebo-controlled, parallel group phase II study of fispemifene in the treatment of low testosterone in older men will seek to enroll approximately 100 patients at approximately 20 study sites in the United States. Patients will receive either 100, 200, or 300 mg fispemifene or placebo for 28 days. The company also started dosing in a...
Source: Drug Week (2006-03-24)
|
